Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in...

Area of Science:

• Cardiology
• Oncology
• Biochemistry

Background:

• Doxorubicin is a vital chemotherapy drug.
• It can cause dose-dependent cardiomyopathy, limiting its use.
• The sarcoplasmic reticulum (SR) may be an early target in this damage.

Purpose of the Study:

• To investigate changes in SR calcium pump and release channel proteins during doxorubicin treatment.
• To correlate these changes with cardiomyopathy severity and functional deficits.

Main Methods:

• Rabbits received chronic doxorubicin treatment.
• Cardiomyopathy was assessed via microscopy.
• SR protein levels and function ([3H]ryanodine binding, Western blot) were measured in heart and skeletal muscle.

Main Results:

• Doxorubicin significantly decreased [3H]ryanodine binding and ryanodine receptor levels in heart SR.
• These decreases correlated with cardiomyopathy severity and reduced atrial contractility.
• No changes were observed in the SR calcium pump protein or in skeletal muscle SR.

Conclusions:

• Doxorubicin-induced cardiomyopathy involves a reduction in cardiac sarcoplasmic reticulum calcium release channels (ryanodine receptors).
• This dysfunction likely contributes to the observed contraction and relaxation abnormalities.
• The calcium pump protein remains unaffected, suggesting a specific impact on the release channel.